Although Paclitaxel Coated Devices Confer No Increase In Mortality Rates, They May Still Be Associated With Increased Amputation Rates When Used To Treat CLTI Patients: What Mechanism May Be Responsible

Increased Amputation Rates From Use Of Paclitaxel Coated Devices May Be Real Or A Methodological Artifact: Other Paclitaxel Coating Effects Like Embolization Or Post Atherectomy Aneurysm Formation Deserve Further Study

Comparative Long-Term Outcomes With DESs And DCBs To Treat Fem-Pop Lesions: Unique Observations After 2-12 Years In 1000 Patients: What Is The Best Technique For Vessel Preparation

2-Year Results Of The SPORTS RCT Comparing DESs (Eluvia ndash; Boston Scientific) vs. Bare Metal Stents (BMSs) vs. DCBs: Which Device Is Best And In What Circumstances

Long-Term Results Of An RCT Comparing SurVeil DCBs (Surmodics) With In.Pact DCBs (Medtronic) For Treating Fem-Pop Lesions: From The TRANSCEND Trial: How Do The Two Devices Differ

DESs vs. Bare Stents: Data From The TRUETA Trial: What New Information Influencing Practice Comes From This Large Data Analysis

Systematic Literature Review And Meta-Analysis Of Fem-Pop Endovascular Treatment With DESs, Cover Stents And BMSs: When Is Each Best And What Is The Hard Evidence

Directional Atherectomy As Vessel Prep For DCB Use For Fem-Pop Lesions: For Which Lesion Characteristics Is It The Best Treatment: What Is The Evidence For Its Superiority

Panel Discussion

12 Commandments For A Successful BTK Intervention In Patients With CLTI

What's New And What's Next For The Treatment Of BTK Lesions: When Is POBA Still Acceptable And What About Drug Eluting And Non-Drug Eluting Devices, Resorbable Or Not

Updated 2-Year Results Of The DEBATE-BTK SHOCK RCT Evaluating The Value Of Lithotripsy (Shockwave-J&J) Prior To DCB Treatment In Diabetic Patients Undergoing BTK Revascularization

Patency And Wound Healing Results Of The 3-French Compatible Microstent (From Micro Medical) Compare Favorably With POBA For BTK Lesions: From The STAND RCT: Antegrade And Retrograde Insertions Are Possible

Update On The SELUTION4BTK RCT Comparing A Sirolimus-Coated DCB (From Cordis/Medalliance) With POBA For BTK Lesions

Why Some BTK DCB Trials Have Not Shown Uniformly Better Results: Technical And Balloon Factors Matter

Late (5-Year) Results From The AcoArt II BTK DCB RCT Show Safety With No Increased Mortality And Improved Patency vs. POBA To Treat BTK Lesions

Open vs. Endo Revascularization For Patients With Infrapopliteal Disease Causing CLTI: A Large Population Based Study Confirms The Superiority Of Saphenous Vein Bypass: Newer Technologies May Alter This Conclusion

Panel Discussion

Lunch Break - Rhinelander Gallery, 2nd Floor
Visit Exhibits And Pavilions (2nd and 3rd Floors)